Last reviewed · How we verify
Remifentanil Laboratorios Chalver de Colombia S.A.
Remifentanil Laboratorios Chalver de Colombia S.A. is a Small molecule drug developed by Fundación Universitaria de Ciencias de la Salud. It is currently FDA-approved.
Remifentanil, marketed by Laboratorios Chalver de Colombia S.A., is an opioid analgesic with a well-established presence in the market. The drug's key composition patent is set to expire in 2028, providing a significant period of exclusivity. However, the lack of reported revenue and primary trial results poses a risk in assessing its competitive landscape and market performance.
At a glance
| Generic name | Remifentanil Laboratorios Chalver de Colombia S.A. |
|---|---|
| Sponsor | Fundación Universitaria de Ciencias de la Salud |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil Laboratorios Chalver de Colombia S.A. CI brief — competitive landscape report
- Remifentanil Laboratorios Chalver de Colombia S.A. updates RSS · CI watch RSS
- Fundación Universitaria de Ciencias de la Salud portfolio CI